BridgeMD
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA)
EU CTIS ID: 2024-512436-29-00
What this study is testing
To find out if the de-escalation from the more powerful antiplatelet agents prasugrel and ticagrelor to clopidogrel, guided by the VerifyNow® platelet aggregation measurement device, has a beneficial effect in the treatment of ACS.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with age 18 years or above; Patient is able to understand the nature of study and has provided written informed consent; Patients with Acute Coronary Syndrome and who underwent PCI during the admission with absorbable polymer stent who have been discharged on double antiplatelet therapy with Acetylsalicylic Acid and Ticagrelor or Prasugrel
You likely can't join if
- Patients with history of intracranial bleeding; Patients with contraindication for the use of Acetylsalicylic Acid or Clopidogrel or Ticagrelor or Prasugrel; Patients with major ischemic or hemorrhagic events during the first month; Patients with Thrombocytopenia <50,000 /μL; Patients with permanent oral anticoagulation; Patient is pregnant or breast feeding;Patients with impossibility to complete 1 year of follow-up; Patient´s life-expectancy is less than 24 months
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.